Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;33(12):13683-13694.
doi: 10.1096/fj.201901278R. Epub 2019 Sep 28.

Gα13-mediated LATS1 down-regulation contributes to epithelial-mesenchymal transition in ovarian cancer

Hiroshi Yagi  1 , Ichiro Onoyama  1 , Kazuo Asanoma  1 , Emiko Hori  1 , Masafumi Yasunaga  1 , Keisuke Kodama  1 , Masako Kijima  1 , Tatsuhiro Ohgami  1 , Eisuke Kaneki  1 , Kaoru Okugawa  1 , Hideaki Yahata  1 , Kiyoko Kato  1
Affiliations

Gα13-mediated LATS1 down-regulation contributes to epithelial-mesenchymal transition in ovarian cancer

Hiroshi Yagi et al. FASEB J. 2019 Dec.

Abstract

Gα13, a heterotrimeric G-protein of the Gα12/13 subfamily, is associated with aggressive phenotypes in various human cancers. However, the mechanisms by which Gα13 promotes cancer progression have not been fully elucidated. Here, we demonstrate that the activation of Gα13 induces epithelial-mesenchymal transition in ovarian cancer (OvCa) cells through down-regulation of large tumor suppressor kinase (LATS) 1, a critical component of the Hippo signaling pathway. A synthetic biology approach using a mutant GPCR and chimeric G-protein revealed that Gα13-regulated phosphorylation of LATS1 at serine 909 within its activation loop induced recruitment of the itchy E3 ubiquitin protein ligase to trigger LATS1 degradation. Our findings uncover novel mechanisms through which Gα13 activation induces dysregulation of the Hippo signaling pathway, which leads to aggressive cancer phenotypes, and thereby identify a potential target for preventing the metastatic spread of OvCa.-Yagi, H., Onoyama, I., Asanoma, K., Hori, E., Yasunaga, M., Kodama, K., Kijima, M., Ohgami, T., Kaneki, E., Okugawa, K., Yahata, H., Kato, K. Gα13-mediated LATS1 down-regulation contributes to epithelial-mesenchymal transition in ovarian cancer.

Keywords: EMT; GPCR; Hippo signaling pathway; ITCH; ubiquitination.

PubMed Disclaimer

References

REFERENCES

    1. Siegel, R. L., Miller, K. D., and Jemal, A. (2018) Cancer statistics, 2018. CA Cancer J. Clin. 68, 7-30
    1. Dorsam, R. T., and Gutkind, J. S. (2007) G-protein-coupled receptors and cancer. Nat. Rev. Cancer 7, 79-94
    1. Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., Moorhead, M., Chaudhuri, S., Tomsho, L. P., Peters, B. A., Pujara, K., Cordes, S., Davis, D. P., Carlton, V. E., Yuan, W., Li, L., Wang, W., Eigenbrot, C., Kaminker, J. S., Eberhard, D. A., Waring, P., Schuster, S. C., Modrusan, Z., Zhang, Z., Stokoe, D., de Sauvage, F. J., Faham, M., and Seshagiri, S. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873
    1. Robertson, A. G., Shih, J., Yau, C., Gibb, E. A., Oba, J., Mungall, K. L., Hess, J. M., Uzunangelov, V., Walter, V., Danilova, L., Lichtenberg, T. M., Kucherlapati, M., Kimes, P. K., Tang, M., Penson, A., Babur, O., Akbani, R., Bristow, C. A., Hoadley, K. A., Iype, L., Chang, M. T., Cherniack, A. D., Benz, C., Mills, G. B., Verhaak, R. G. W., Griewank, K. G., Felau, I., Zenklusen, J. C., Gershenwald, J. E., Schoenfield, L., Lazar, A. J., Abdel-Rahman, M. H., Roman-Roman, S., Stern, M. H., Cebulla, C. M., Williams, M. D., Jager, M. J., Coupland, S. E., Esmaeli, B., Kandoth, C., and Woodman, S. E.; TCGA Research Network. (2017) Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32, 204-220.e15; erratum: 33, 151
    1. Domingo, E., Camps, C., Kaisaki, P. J., Parsons, M. J., Mouradov, D., Pentony, M. M., Makino, S., Palmieri, M., Ward, R. L., Hawkins, N. J., Gibbs, P., Askautrud, H., Oukrif, D., Wang, H., Wood, J., Tomlinson, E., Bark, Y., Kaur, K., Johnstone, E. C., Palles, C., Church, D. N., Novelli, M., Danielsen, H. E., Sherlock, J., Kerr, D., Kerr, R., Sieber, O., Taylor, J. C., and Tomlinson, I. (2018) Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. Lancet Gastroenterol. Hepatol. 3, 635-643

Publication types

MeSH terms

Substances